ArticleNature biotechnology2026
Zero-shot de novo peptide sequencing with open posttranslational modification discovery.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
De novo peptide sequencing directly infers sequences from mass spectrometry data without relying on protein databases. Although recent deep learning models can also identify posttranslational modifications (PTMs), they require labeled training data for this task. Here we introduce rotary positional embedding-enhanced de novo sequencing algorithm (RNovA), a transformer-based de novo sequencing algorithm enhanced with relative positional embeddings and a reinforcement-learning-style sequential decision framework. RNovA enables open PTM discovery in a zero-shot setting-without retraining or a predefined list of candidate residues-while maintaining state-of-the-art performance on standard benchmarks. Demonstrating this capability, we successfully identified peptides modified by kynurenine-an uncommon and biologically relevant PTM-in clinical samples from patients with RA and validated this discovery with synthetically synthesized reference peptides. Furthermore, we demonstrated open de novo PTM discovery by analyzing the bacterial strain A1232E, which lacks a reference proteome, and detected an unannotated glutamic acid modification. RNovA enables exploration of previously inaccessible regions of the proteome, including peptides with unexpected or unannotated modifications.
Identifiers
42156534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.